Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis

Rodney P. Rocconi, Jacob M. Estes, Charles A. Leath, Larry Kilgore, Warner K. Huh, J. Michael Straughn

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective. To assess the potential effectiveness and medical costs of three common strategies to manage Stage IB2 squamous cell carcinoma of the cervix (CXCA). Methods. A decision analysis model compared three strategies to manage Stage IB2 CXCA: (1) radical hysterectomy with pelvic and para-aortic lymphadenectomy followed by tailored chemoradiation therapy for high-risk patients (RHYST); (2) primary chemoradiation therapy for all patients (CTRT); and (3) neoadjuvant chemotherapy followed by radical hysterectomy and tailored chemoradiation therapy for high-risk patients (NAC). Results. RHYST was the least expensive strategy with a cost of 284 Million (M) per 10,000 women and a 5-year disease free survival (5-DFS) of 69%. Both NAC and CTRT had similar 5-DFS (69.3% and 70%, respectively); however, both NAC and CTRT were more expensive than RHYST at 299 M and 508 M, respectively. This translated into a higher cost-effectiveness ratio for NAC and CTRT ($43,197 and $72,613, respectively) when compared to RHYST ($41,212). NAC yielded 30 additional survivors compared to RHYST but at a cost of $499,783 per survivor. CTRT was more effective than RHYST with 100 additional survivors but at a substantial cost of $2,240,000 per survivor. Conclusions. RHYST is the most cost-effective strategy to manage Stage IB2 CXCA and would be favored in settings where resources are limited. Although NAC and CTRT are reasonable treatment strategies, policymakers must be willing to spend approximately $500,000 per additional survivor (NAC) or $2.2 M per additional survivor (CTRT).

Original languageEnglish (US)
Pages (from-to)387-394
Number of pages8
JournalGynecologic Oncology
Volume97
Issue number2
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Uterine Cervical Neoplasms
Cost-Benefit Analysis
Survivors
Costs and Cost Analysis
Hysterectomy
Disease-Free Survival
Decision Support Techniques
Therapeutics
Lymph Node Excision
Cervix Uteri
Squamous Cell Carcinoma
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Management strategies for stage IB2 cervical cancer : A cost-effectiveness analysis. / Rocconi, Rodney P.; Estes, Jacob M.; Leath, Charles A.; Kilgore, Larry; Huh, Warner K.; Straughn, J. Michael.

In: Gynecologic Oncology, Vol. 97, No. 2, 01.01.2005, p. 387-394.

Research output: Contribution to journalArticle

Rocconi, Rodney P. ; Estes, Jacob M. ; Leath, Charles A. ; Kilgore, Larry ; Huh, Warner K. ; Straughn, J. Michael. / Management strategies for stage IB2 cervical cancer : A cost-effectiveness analysis. In: Gynecologic Oncology. 2005 ; Vol. 97, No. 2. pp. 387-394.
@article{43ab792e521e4acfbbd962d4baefcdeb,
title = "Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis",
abstract = "Objective. To assess the potential effectiveness and medical costs of three common strategies to manage Stage IB2 squamous cell carcinoma of the cervix (CXCA). Methods. A decision analysis model compared three strategies to manage Stage IB2 CXCA: (1) radical hysterectomy with pelvic and para-aortic lymphadenectomy followed by tailored chemoradiation therapy for high-risk patients (RHYST); (2) primary chemoradiation therapy for all patients (CTRT); and (3) neoadjuvant chemotherapy followed by radical hysterectomy and tailored chemoradiation therapy for high-risk patients (NAC). Results. RHYST was the least expensive strategy with a cost of 284 Million (M) per 10,000 women and a 5-year disease free survival (5-DFS) of 69{\%}. Both NAC and CTRT had similar 5-DFS (69.3{\%} and 70{\%}, respectively); however, both NAC and CTRT were more expensive than RHYST at 299 M and 508 M, respectively. This translated into a higher cost-effectiveness ratio for NAC and CTRT ($43,197 and $72,613, respectively) when compared to RHYST ($41,212). NAC yielded 30 additional survivors compared to RHYST but at a cost of $499,783 per survivor. CTRT was more effective than RHYST with 100 additional survivors but at a substantial cost of $2,240,000 per survivor. Conclusions. RHYST is the most cost-effective strategy to manage Stage IB2 CXCA and would be favored in settings where resources are limited. Although NAC and CTRT are reasonable treatment strategies, policymakers must be willing to spend approximately $500,000 per additional survivor (NAC) or $2.2 M per additional survivor (CTRT).",
author = "Rocconi, {Rodney P.} and Estes, {Jacob M.} and Leath, {Charles A.} and Larry Kilgore and Huh, {Warner K.} and Straughn, {J. Michael}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2005.01.028",
language = "English (US)",
volume = "97",
pages = "387--394",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Management strategies for stage IB2 cervical cancer

T2 - A cost-effectiveness analysis

AU - Rocconi, Rodney P.

AU - Estes, Jacob M.

AU - Leath, Charles A.

AU - Kilgore, Larry

AU - Huh, Warner K.

AU - Straughn, J. Michael

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Objective. To assess the potential effectiveness and medical costs of three common strategies to manage Stage IB2 squamous cell carcinoma of the cervix (CXCA). Methods. A decision analysis model compared three strategies to manage Stage IB2 CXCA: (1) radical hysterectomy with pelvic and para-aortic lymphadenectomy followed by tailored chemoradiation therapy for high-risk patients (RHYST); (2) primary chemoradiation therapy for all patients (CTRT); and (3) neoadjuvant chemotherapy followed by radical hysterectomy and tailored chemoradiation therapy for high-risk patients (NAC). Results. RHYST was the least expensive strategy with a cost of 284 Million (M) per 10,000 women and a 5-year disease free survival (5-DFS) of 69%. Both NAC and CTRT had similar 5-DFS (69.3% and 70%, respectively); however, both NAC and CTRT were more expensive than RHYST at 299 M and 508 M, respectively. This translated into a higher cost-effectiveness ratio for NAC and CTRT ($43,197 and $72,613, respectively) when compared to RHYST ($41,212). NAC yielded 30 additional survivors compared to RHYST but at a cost of $499,783 per survivor. CTRT was more effective than RHYST with 100 additional survivors but at a substantial cost of $2,240,000 per survivor. Conclusions. RHYST is the most cost-effective strategy to manage Stage IB2 CXCA and would be favored in settings where resources are limited. Although NAC and CTRT are reasonable treatment strategies, policymakers must be willing to spend approximately $500,000 per additional survivor (NAC) or $2.2 M per additional survivor (CTRT).

AB - Objective. To assess the potential effectiveness and medical costs of three common strategies to manage Stage IB2 squamous cell carcinoma of the cervix (CXCA). Methods. A decision analysis model compared three strategies to manage Stage IB2 CXCA: (1) radical hysterectomy with pelvic and para-aortic lymphadenectomy followed by tailored chemoradiation therapy for high-risk patients (RHYST); (2) primary chemoradiation therapy for all patients (CTRT); and (3) neoadjuvant chemotherapy followed by radical hysterectomy and tailored chemoradiation therapy for high-risk patients (NAC). Results. RHYST was the least expensive strategy with a cost of 284 Million (M) per 10,000 women and a 5-year disease free survival (5-DFS) of 69%. Both NAC and CTRT had similar 5-DFS (69.3% and 70%, respectively); however, both NAC and CTRT were more expensive than RHYST at 299 M and 508 M, respectively. This translated into a higher cost-effectiveness ratio for NAC and CTRT ($43,197 and $72,613, respectively) when compared to RHYST ($41,212). NAC yielded 30 additional survivors compared to RHYST but at a cost of $499,783 per survivor. CTRT was more effective than RHYST with 100 additional survivors but at a substantial cost of $2,240,000 per survivor. Conclusions. RHYST is the most cost-effective strategy to manage Stage IB2 CXCA and would be favored in settings where resources are limited. Although NAC and CTRT are reasonable treatment strategies, policymakers must be willing to spend approximately $500,000 per additional survivor (NAC) or $2.2 M per additional survivor (CTRT).

UR - http://www.scopus.com/inward/record.url?scp=18144366151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144366151&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.01.028

DO - 10.1016/j.ygyno.2005.01.028

M3 - Article

C2 - 15863134

AN - SCOPUS:18144366151

VL - 97

SP - 387

EP - 394

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -